Tazarotene - Almirall

Drug Profile

Tazarotene - Almirall

Alternative Names: LAS41006

Latest Information Update: 28 Jul 2015

Price : $50

At a glance

  • Originator Almirall S.A.
  • Class Antiacnes; Antipsoriatics; Keratolytics; Nicotinic-acids; Retinoids; Small molecules
  • Mechanism of Action Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Psoriasis

Most Recent Events

  • 07 May 2015 Almirall completes a phase II trial in Psoriasis in Germany (NCT02235480)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top